Literature DB >> 15803004

Prostate biopsy volume indices do not predict for significant Gleason upgrading.

Christopher R King1, Deep A Patel, Martha K Terris.   

Abstract

Significant discordance exists between biopsy and matched prostatectomy grades. This study tests the hypothesis that surrogate tumor volume indices available from biopsies could yield an improved prediction of the underlying pathologic Gleason grade. Records of 124 patients who underwent radical prostatectomy were reviewed. Biopsies were characterized by primary and secondary Gleason grade, number of positive cores, and linear tumor length. Surgical specimens were characterized by primary and secondary Gleason grade, organ-confined disease, seminal vesicle invasion, and margins. Biochemical failure (BF) was defined by a postoperative prostate-specific antigen >0.05 ng/mL. There were 28 patients (24%) who experienced biochemical failure. On multivariate analysis, only the pathologic Gleason sum (P = 0.012) and the cumulative tumor length (P = 0.050) were independently associated with BF, and only the cumulative tumor length was associated with nonorgan-confined disease (P = 0.034). For patients with a cumulative tumor length >10 mm, 49% (18 of 37) had nonorgan-confined disease and 37% (13 of 35) had BF compared with 29% (25 of 87) and 19% (15 of 80), respectively, if they had cumulative tumor length < or =10 mm (P <0.034). Overall, an exact match was seen in 39% of biopsy Gleason grades, whereas 21% were downgraded by 1 or more points, and 41% were upgraded by 1 or more points. On univariate or multivariate analysis, none of the biopsy surrogate volume indices examined achieved significance or suggested a trend in predicting for a clinically meaningful grade change. Although indices of tumor volume from prostate needle biopsies independently predict for organ-confined disease and BF after prostatectomy, none predicted for a clinically significant upgrading or downgrading of biopsies. This suggests that the correlation that exists between such volume surrogates and outcomes after surgery reflect tumor volume effects only, independently of any possible association between tumor volume and Gleason grade.

Entities:  

Mesh:

Year:  2005        PMID: 15803004     DOI: 10.1097/01.coc.0000143848.24158.c3

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  5 in total

1.  Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6.

Authors:  Vikas Mehta; Kevin Rycyna; Bart M M Baesens; Güliz A Barkan; Gladell P Paner; Robert C Flanigan; Eva M Wojcik; Girish Venkataraman
Journal:  Int J Clin Exp Pathol       Date:  2012-07-29

2.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.

Authors:  Jonathan I Epstein; Zhaoyong Feng; Bruce J Trock; Phillip M Pierorazio
Journal:  Eur Urol       Date:  2012-02-08       Impact factor: 20.096

3.  Upgrading of Gleason score on radical prostatectomy specimen compared to the pre-operative needle core biopsy: an Indian experience.

Authors:  Rishi Nayyar; Prabhjot Singh; Narmada P Gupta; Ashok K Hemal; Prem N Dogra; Amlesh Seth; Rajeev Kumar
Journal:  Indian J Urol       Date:  2010 Jan-Mar

4.  Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy.

Authors:  Sung Kyu Hong; Byung Kyu Han; Seung Tae Lee; Sung Soo Kim; Kyung Eun Min; Sung Jin Jeong; Hyeon Jeong; Seok-Soo Byun; Hak Jong Lee; Gheeyoung Choe; Sang Eun Lee
Journal:  World J Urol       Date:  2008-11-20       Impact factor: 4.226

5.  Development and External Validation of a Nomogram Predicting the Probability of Significant Gleason Sum Upgrading among Japanese Patients with Localized Prostate Cancer.

Authors:  Takashi Imamoto; Takanobu Utsumi; Makoto Takano; Atsushi Komaru; Satoshi Fukasawa; Takahito Suyama; Koji Kawamura; Naoto Kamiya; Junichiro Miura; Hiroyoshi Suzuki; Takeshi Ueda; Tomohiko Ichikawa
Journal:  Prostate Cancer       Date:  2010-11-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.